Medtronic (XSWX:MDT) 10-Year RORE % : 0.36% (As of Apr. 2026)


XSWX:MDT Medtronic PLC XSWX:MDT
21 GF Score
Price CHF65.29
GF Value CHF80.97
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medtronic 10-Year RORE %?

Medtronic XSWX:MDT +1.21% 21 10-Year RORE % is 0.36 as of Apr. 2026. GuruFocus rates XSWX:MDT with a GF Score™ of 21/100 and a GF Value™ of CHF80.97 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 429 Medical Devices & Instruments companies, Medtronic ranks better than 69.46% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Medtronic's 10-Year RORE % for the quarter that ended in Apr. 2026 was 0.36%.

The industry rank for Medtronic's 10-Year RORE % or its related term are showing as below:

XSWX:MDT's 10-Year RORE % is ranked better than
69.46% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 0.42 vs XSWX:MDT: 0.36

Medtronic  (XSWX:MDT) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Medtronic 10-Year RORE % Related Terms


Medtronic 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Medtronic's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtronic 10-Year RORE % Chart

Medtronic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 -0.51 -0.33 3.34 0.36

Medtronic Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.34 2.52 0.58 0.43 0.36

XSWX:MDT vs SYK, BSX, EW: 10-Year RORE % Comparison

For the Medical Devices subindustry, Medtronic's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medtronic 10-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medtronic's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Medtronic's 10-Year RORE % falls into.


XSWX:MDT
21GF Score
Medtronic PLC XSWX:MDT
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtronic 10-Year RORE % Calculation

Medtronic's 10-Year RORE % for the quarter that ended in Apr. 2026 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 2.959-2.874 )/( 29.044-5.151 )
=0.085/23.893
=0.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Apr. 2026 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 0.36 mean?
Medtronic (XSWX:MDT) has a 10-Year RORE % of 0.36 as of Apr. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Medtronic and its competitors. According to the industry distribution chart, Medtronic ranks #131 out of 429 companies in the Medical Devices & Instruments industry, placing it in the top 30.5%.
Is Medtronic's 10-Year RORE % too high?
Medtronic's current 10-Year RORE % is 0.36. The Medical Devices & Instruments industry median 10-Year RORE % is 0.42. Medtronic's value of 0.36 is 14.3% below this industry median. Based on the distribution chart, Medtronic ranks #131 out of 429 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medtronic has a GF Score™ of 21/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's 10-Year RORE % compare to SYK and BSX?
According to the Medical Devices & Instruments industry distribution chart, Medtronic ranks #131 out of 429 companies for 10-Year RORE %. This puts Medtronic in the upper half of its industry. The industry median 10-Year RORE % is 0.42. Medtronic's value of 0.36 is 14.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 0.42, based on 429 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtronic's current 10-Year RORE % of 0.36 is 14.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Medtronic and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtronic's current 10-Year RORE % is 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (XSWX:MDT) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF80.97, compared to a current price of CHF65.29 — trading 19.4% below its estimated fair value. The current 10-Year RORE % is 0.36 and 14.3% below the Medical Devices & Instruments industry median of 0.42. Medtronic's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Medtronic (XSWX:MDT), the current 10-Year RORE % is 0.36 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medtronic (XSWX:MDT) Overvalued in 2026?

Based on GuruFocus' analysis, Medtronic stock appears to be undervalued. The current stock price of CHF65.29 is trading 19.4% below its estimated GF Value™ of CHF80.97. GuruFocus considers Medtronic to be Modestly Undervalued.

Key valuation signals for XSWX:MDT:

  • 10-Year RORE %: 0.36
  • GF Value™: CHF80.97 vs. price of CHF65.29 (19.4% below fair value)
  • GF Score™: 21/100 with 3 warning signs
  • Industry Position: 14.3% below the Medical Devices & Instruments median (#131 of 429)

No single metric tells the full story. See the XSWX:MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medtronic Business Description

Address Parkmore Business Park West, Building Two, Galway, IRL
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
21GF Score

Get the complete analysis for XSWX:MDT

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF65.29
Price
CHF80.97
GF Value